by | Apr 15, 2024 | Publications
Mol Ther Nucleic Acids. 2024 Apr 6;35(2):102180. doi: 10.1016/j.omtn.2024.102180. eCollection 2024 Jun 11. NO ABSTRACT PMID:38617975 | PMC:PMC11015496 | DOI:10.1016/j.omtn.2024.102180
by | Apr 15, 2024 | Publications
Transplant Cell Ther. 2024 Apr 12:S2666-6367(24)00347-6. doi: 10.1016/j.jtct.2024.04.007. Online ahead of print. ABSTRACT Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However,...
by | Apr 14, 2024 | Publications
Blood Cancer J. 2024 Apr 12;14(1):64. doi: 10.1038/s41408-024-01049-z. NO ABSTRACT PMID:38609377 | DOI:10.1038/s41408-024-01049-z
by | Apr 14, 2024 | Publications
Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0. NO ABSTRACT PMID:38609386 | DOI:10.1038/s41408-024-00993-0
by | Apr 14, 2024 | Publications
Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02237-3. Online ahead of print. ABSTRACT Growing evidence suggests that gain or amplification [gain/amp(1q)] accumulates during disease progression of multiple myeloma (MM). Previous investigations have indicated that...
by | Apr 14, 2024 | Publications
Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05730-y. Online ahead of print. ABSTRACT Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The...
